All Categories
ENEN
Liraglutide

Liraglutide 日本

Home >  Modality  >  Proteins  >  GLP-1  >  Liraglutide

Modality

Liraglutide

Description of Liraglutide

Liraglutide is a biosynthetic GLP-1 analogue, with 97% amino acid residue identity to natural GLP-1 (7-37). Novo developed two formulations of liraglutide available in the market, i.e., Victoza and Saxenda for glycemic control (1.2-1.8 mg daily) and weight management (3 mg daily), respectively.

 

Synonyms

LATIN T1D, Liraglutide (Genetical Recombination), NEX 22, NN 2211, NN 9211, NN-8022,  NNC 90-1170, SAXE, Saxenda, Victoza, 诺和力, ビクトーザ

 

Amino Acid Sequence of Liraglutide

The differences between Liraglutide and human GLP-1 (7-37) are that Lys is replaced by Arg at position 28; glutamate spacer at Lys in position 20 conjugates palmitic acid. Through binding to serum albumin and self-binding in the subcutaneous space, fatty acid conjugation prolongs the duration of action.

Fig.1 Structure formula of liraglutide

 

Expression System of Liraglutide

Yeast (Saccharomyces cerevisiae)

Some liraglutide biosimilars are produced in bacteria (Escherichia coli).

 

Formulation of Liraglutide

Inactive ingredients in Victoza/ Saxenda

Disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14 mg; phenol, 5.5 mg; and water for injection.

 

Manufacturing Process of Liraglutide
Drug Substance Manufacturing
  • Yeast fermentation and culture broth harvesting
  • Purification to produce pure liraglutide precursor
  • Acylation of the liraglutide precursor and purification to produce drug substance.

 

Drug Product Manufacturing
  • Aseptic Fill-Finish: formulation preparation and filling into cartridges

 

Yaohai Bio-Pharma offers One-Stop CDMO Solution for Liraglutide

 

Get a Free Quote

Get in touch